Dyadic's First Real Revenue Quarter Was Also Its Quietest Surrender
The long-promised commercial transition arrived at $449,000 — and management finally stopped pretending the ramp was imminent
DYAI · Earnings Call · 2026-11-12
The $449,000 Quarter
Dyadic International reported third-quarter 2026 revenue of roughly $449,000, down 61% from about $1.165 million a year earlier. CFO Ping Rawson broke it down: $162,000 of research and development revenue, $276,000 of grant revenue, $10,000 of license fees. Add them up and you have essentially the whole quarter. Which is the story. Because the call opened with President and COO Joe Hazelton announcing that “Dyadic recorded its first direct commercial protein product sales, primarily involving recombinant transferrin and DNase I.” — Joseph Hazelton, President and COO · 2026-11-12 The first product revenue of this kind in company history — and it does not appear as a line you can point to. Hazelton said so himself: those sales "are not yet financially material." The milestone is real and long-awaited. It is also, at current scale, economically indistinguishable from zero. He then set expectations before anyone else could: “Our direct commercial sales remain modest and customer qualification and adoption are taking longer than we originally anticipated.” — Joseph Hazelton, President and COO · 2026-11-12 For a company whose entire equity story for six quarters has been "we are transitioning from a development shop to a commercial business," that sentence is the quarter.The Promise That Quietly Expired
Go back to the August 2025 call. A private investor asked when Dyadic crosses over to profitability. Hazelton answered: “The goal is that we're cash flow positive by the end of 2026, and then we start to see increased profitability in 2027 and beyond.” — Joseph P. Hazelton · 2025-08-13 That end-of-2026 date is now roughly seven weeks away. On this call nobody mentioned it. What they mentioned instead was about $6 million of cash, cash equivalents, restricted cash and investment-grade securities against net operating cash use of roughly $590,000 per month — arithmetic that lands you near the end of the runway — alongside a $2.9 million registered direct offering completed during the quarter. And then this, tucked into the strategic section rather than the financial one:The balance sheet itself is worth a look. Liabilities to assets crossed 100%, up 16.9 points year over year, after climbing roughly 43 points across the last twelve months. Market value has compressed accordingly: price-to-revenue sits at 7.8x versus a June 2020 peak near 138x. The tape tells the same tale: the stock is down 69% over the last 90 trading days and 77.8% from its July peak of $1.47, and remains 96.8% below its 2020 high. There is a recurring rhythm worth naming. A year ago, the last question on the November 2025 call was again about the burn: “Can you comment on the burn and, yeah, how much ability you have to do what you need to?” — Tony Bowers, Analyst · 2025-11-12 Four quarters later the answer is structurally the same — a few million of cash in, a few million of cash out, and a partner payment landing in the fourth quarter to dress the year-end print. This year that payment is $225,000 from Inzymes, tied to its first commercial sale of Dapibus-produced camel chymosin in October, to be recognized in Q4. A one-time partner check in the final quarter is becoming a Dyadic habit rather than an accident.We continue to evaluate all options to maximize the value of our platforms and assets, including financing alternatives, strategic partnerships and other opportunities to strengthen our balance sheet.